Bing

Amarin Co. plc (NASDAQ:AMRN) CEO John F. Thero acquired 20,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was bought at an average price of $2.35 per share, with a total value of $47,000.00. Following the …
Ticker Report · 8/12/2015
One stock that might be an intriguing choice for investors right now is Amarin Corporation plc ( AMRN). This is because this security in the Medical - Biomed/Genetics space is seeing solid earnings estimate revision activity, and is in great company from a ...
NASDAQ · 4/9/2015
BEDMINSTER, N.J., and DUBLIN, Ireland, Oct 16, 2013 (GLOBE NEWSWIRE via COMTEX) -- Amarin Corporation plc AMRN, -0.90% a biopharmaceutical company focused on the commercialization and development of therapeutics to improve …
Market Watch · 10/16/2013
Amarin Co. plc (NASDAQ:AMRN)‘s stock had its “sector perform” rating restated by equities researchers at Oppenheimer in a research report issued on Tuesday. Amarin Co. plc (NASDAQ:AMRN) opened at 2.30 on Tuesday. Amarin Co. plc has a …
Mideast Times · 6/3/2015
A US judged barred the FDA from stopping Amarin Corp plc (NASDAQ: AMRN) from promoting its fish oil drug Vasecpa off label, according to reports from Reuters. The preliminary order means Amarin can promote its pill to doctors for off-label use as long …
StreetInsider · 8/7/2015
New York, NY - (ACCESSWIRE) - 11/22/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Micron Technology Inc. (NASDAQ:MU), Amarin Corporation plc (NASDAQ …
4 Traders · 11/22/2013
AMRN) on February 18th at $1.38. Now look at the price of the stock, it’s 26% from our buy call and now at $1.75. This is how easy money they made. It’s not yet late, join us at specialpennystockalert.com@gmail.com
Market News Call · 2/26/2015
AuRico Gold Inc. (AUQ) of the Basic Materials sector is down -0.56% (change from open -0.28%) this morning trading at a volume of 206,130 shares and price of $3.52. AuRico Gold Inc. (AUQ)’s weekly performance is 3.51% and compared to their 52 …
wallstreetscope.com · 4/24/2015
With this in mind, here are three biotech stocks that have a reasonable chance to double by next summer. 1. Amarin (NASDAQ: AMRN ) Amarin's stock has dropped like a sinking fastball over the past year. Shares are down more than 60% since last …
The Motley Fool · ByKeith Speights · 7/13/2013
The shares of AMRN are up 30.1% at an annual high of $2.54, after Wainwright & Co quadrupled its price target to $10, and upgraded the stock to "buy." Year-to-date, Amarin Corporation plc is up a staggering 158.2%. Accordingly, calls are popular in the ...
Schaeffer's Investment Research · 3/12/2015

Amarin Corporation

Company
Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets me…
Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. Amarin develops the drug Vascepa which is a prescription grade omega-3 fatty acid. In December 2007, the company acquired Ester Neurosciences Limited for 8.1 million USD. Amarin CEO Joe Zakrzewski has said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States. Recently on July 26, 2012, their lead-candidate drug named Vascepa received FDA-approval. Vascepa will also be a key competitor against GlaxoSmithKline's Lovaza.
Data from: Wikipedia